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Abstract
Introduction
The diffusion of multidrug-resistant (MDR) bacteria has created the need to identify risk fac-
tors for acquiring resistant pathogens in patients living in the community.
Objective
To analyze clinical features of patients with community-onset pneumonia due to MDR path-
ogens, to evaluate performance of existing scoring tools and to develop a bedside risk
score for an early identification of these patients in the Emergency Department.
Patients and Methods
This was an open, observational, prospective study of consecutive patients with pneumo-
nia, coming from the community, from January 2011 to January 2013. The new score was
validated on an external cohort of 929 patients with pneumonia admitted in internal medi-
cine departments participating at a multicenter prospective study in Spain.
Results
A total of 900 patients were included in the study. The final logistic regression model con-
sisted of four variables: 1) one risk factor for HCAP, 2) bilateral pulmonary infiltration, 3)
the presence of pleural effusion, and 4) the severity of respiratory impairment calculated by
use of PaO2/FiO2 ratio. A new risk score, the ARUC score, was developed; compared to
Aliberti, Shorr, and Shindo scores, this point score system has a good discrimination
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performance (AUC 0.76, 95% CI 0.71-0.82) and calibration (Hosmer-Lemeshow, χ2 = 7.64;
p = 0.469). The new score outperformed HCAP definition in predicting etiology due to MDR
organism. The performance of this bedside score was confirmed in the validation cohort
(AUC 0.68, 95% CI 0.60-0.77).
Conclusion
Physicians working in ED should adopt simple risk scores, like ARUC score, to select the
most appropriate antibiotic regimens. This individualized approach may help clinicians to
identify those patients who need an empirical broad-spectrum antibiotic therapy.
Introduction
Pneumonia caused by multidrug-resistant (MDR) pathogens traditionally has been confined to
the hospital setting, but the emergence of MDR bacteria that cause pneumonia in the commu-
nity has created the need to identify risk factors for acquiring resistant pathogens by evaluating
the contacts patients have with the healthcare environment [1–2]. Prior hospitalization, resi-
dency in a nursing home, attendance of hemodialysis centers, and receipt of domiciliary care
are some of the risk factors for acquiring the resistant pathogens included in the healthcare-as-
sociated pneumonia (HCAP) definition [3,4,5,6]. Some studies have shown that the current
definition of HCAP is no longer sufficient for early identification of patients with an increased
risk of pneumonia due to MDR bacteria [1,5,7], and more recently three studies [8,9,10] have
proposed new scores to discriminate patients with an increased risk of developing community-
onset pneumonia due to MDR pathogens.
Considering the aforementioned, the aim of our study is a prospective evaluation of patients
with community-onset pneumonia due to MDR pathogens, to compare this population to pa-
tients without a MDR etiology, and to define risk factors and outcomes of patients acquiring
MDR bacteria. Furthermore, the aim is to evaluate the performance of existing scores [8,9,10]
and to derive and to validate a new bedside risk score for an early identification of patients with
community-onset pneumonia due to MDR pathogens in the Emergency Department (ED).
Patients and Methods
Study Design and Study Patients
This was an open, observational, prospective study of consecutive patients coming from the
community who were admitted, from January 2011 to January 2013, in the Policlinico Um-
berto I of Rome, a teaching 1100-bed Hospital. The Institutional Review Board of the Policli-
nico Hospital approved the study. Patients>18 years of age who satisfied the criteria for
pneumonia were included in the study. The patient enrollment process was: consecutive pa-
tients coming from the community and admitted to our hospital from the ED were initially
screened. Two physicians (MF and AR) performed a screening twice per day in the ED looking
for patients with a suspicion of pneumonia. Once patients were identified they signed an in-
formed consent and then were followed during hospitalization until discharge or death. Pa-
tients taking immunosuppressive therapy, patients with hospital-acquired pneumonia (HAP),
or discharged or dead within48 hours were excluded from the final analysis.
Data on previous antibiotic therapy as well as other risk factors for MDR organisms were
derived from the following sources: a) history taken from patients and/or relatives; b) discharge
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letters and summaries if patients were previously hospitalized in other facilities, and c) elec-
tronic charts if patients were previously hospitalized or seen in the clinics at the Policlinico
Umberto I of Rome, Italy.
The following data were recorded: demographics; past medical history; severity of symp-
toms on admission; pneumonia severity index (PSI) and CURB-65 score (confusion, urea ni-
trogen, respiratory rate, blood pressure,>65 years of age) [11]; clinical, laboratory, and
radiological findings on admission; microbiological data; empiric antibiotic therapy; hospital
stay; in-hospital mortality (for a total of 133 variables).
Study Definitions
Pneumonia was defined, according to the standard definitions of the Centers for Disease Con-
trol and Prevention (CDC) [12]. Severe sepsis was defined as sepsis with sepsis-induced organ
dysfunction or tissue hypoperfusion (manifesting as hypotension, elevated lactate, or decreased
urine output); septic shock as severe sepsis plus persistently low blood pressure following the
administration of intravenous fluids [13]. Pleural effusion was detected using by chest X-ray.
Length of hospital stay (LOS) was calculated as the number of days from the date of admission
to the date of discharge or death. We classified patients as having HCAP if they had attended a
hospital or hemodialysis clinic or received intravenous chemotherapy in the past 30 days, had
been admitted to an acute-care hospital for at least 2 days or had surgery in the past 90 days, or
resided in a nursing home or long-term care facility. We classified patients as having hospital-
acquired pneumonia (HAP) if they received their diagnosis after being hospitalized for more
than 72 hours or within 10 days of leaving the hospital.
Microbiological Analysis and Empiric Antibiotic Therapy
Microbiological examinations performed on sputum, urine, and blood during the first 24
hours after admission and according to standards of practice were evaluated for assessment of
microbial etiology. Results of pleural puncture, tracheobronchial aspirates, and bronchoalveo-
lar lavage fluid, when performed, were also considered as well as serologic tests for Chlamydo-
phila pneumoniae, L. pneumophila, orMycoplasma pneumoniae. Clinical isolates obtained
from patients were identified in the Microbiology Laboratory of our hospital using the auto-
matic system VITEK 2 (bioMérieux Inc., Hazelwood, MO) [14]. Antibiotic resistance profiles,
including the MIC for each isolate, were assessed using the abovementioned automatic system.
Microbiological results were reviewed, and a microbiological cause was assigned independently
by 2 of the investigators (MF and AR). The etiology was considered definite if 1 of the following
criteria was met: positive blood culture in the absence of an apparent extrapulmonary focus;
positive bacterial culture of pleural fluid; positive urinary antigen for Legionella pneumophila
(Binax Now, Trinity Biotech); positive urinary antigen for Streptococcus pneumoniae (Binax
Now, Emergo Europe); a bacterial yield in cultures of valid sputum (>25 polymorphonuclear
cells and<10 epithelial cells per power field) of106 colony forming units (CFU)/mL, tra-
cheobronchial aspirates of105 CFU/mL, bronchoalveolar lavage fluid of104 CFU/mL, and
protected specimen brush cultures of103 CFU/mL; and occurrence of seroconversion (a
4-fold rise in immunoglobulin G [IgG] titers for Chlamydophila pneumoniae [1:512] or a rise
in immunoglobulin M [IgM] titers for C. pneumoniae [1:32] andMycoplasma pneumoniae
[any titer]). When 2 microbiological causes were present, the patient was considered to have
a polymicrobial infection. Patients for whom no microbiological tests were performed and pa-
tients with negative microbiological results were considered to have disease of an unknown
etiology.
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A patient was considered to have a MDR pathogens if one of the following was isolated:
methicillin-resistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, extended
spectrum β-lactamase (ESBL)–producing or carbapenem-resistant Enterobacteriaceae. For the
remaining cases MDR was defined as isolation of a bacterial strain non-susceptible to at least
one agent in three or more antimicrobial categories [15].
We defined empirical antibiotic therapy as antibiotics administered on the first day of thera-
py for pneumonia and considered an empirical antibiotic regimen as adherent current interna-
tional guidelines [16–17]. We analyzed the appropriateness of antibiotic therapy for all
patients with an etiologic diagnosis according to susceptibility test criteria for lower respiratory
tract pathogens. We rated an antimicrobial treatment as inadequate if 1 or more of the organ-
isms present were known to have intrinsic resistance or were found to be resistant through
susceptibility testing.
Study Groups and Endpoints
Two study groups were identified among the study population according to the isolation of
MDR bacteria: group “MDR+”, patients with isolation of 1 resistant pathogen, and group
“MDR-“, patients without MDR isolation. The microbiological endpoint was the actual isola-
tion of an MDR pathogen.
The primary objective of this study was an evaluation of the performance of three existing
scoring systems and the derivation of a new scoring tool for the identification of patients with
pneumonia due to MDR organisms.
The secondary objective is an external validation of our score in a multicenter Spanish pop-
ulation of patients with pneumonia.
External validation
The obtained score was validated on an external cohort of adult patients with pneumonia hos-
pitalized in 59 IMDs of 53 Spanish hospitals participating at a prospective observational multi-
center study, carried-out over a 2-week period, first week in February 2013 and second week in
June 2013 (Estudio de Neumonia en Medicina Interna II). Study methods were reported in a
previous study [18]. Briefly, all the participating IMDs reported data on all the adult patients
treated for pneumonia at their departments during the study period through a web site. Col-
lected data were systematically reviewed by the coordinating investigator (MG) before they
were entered in the database.
Statistical analysis
Continuous variables are presented as mean±SD, and differences were evaluated by t-test. Cat-
egorical variables were expressed as count and percentages and compared by chi-square test or
Fisher’s exact test, as appropriate.
We performed logistic regression on MDR isolation to determine the best predictors. We se-
lected potentially useful baseline characteristic predictor variables by minimization of Akaike
Information Criterion (AIC), given that the main target for analysis is prediction. For reasons
of parsimony, we then discarded non-significant variables from the model minimizing AIC.
Model stability and absence of collinearity was checked by computing Variance Inflaction Fac-
tors (VIF). A VIF< 3 usually indicates no issues with the model. Candidate variables included:
demographic characteristics (age, sex),2 comorbidities, pleural effusion, HCAP, PaO2/FiO2
<300, bilateral pulmonary infiltration, fever> 38°C. A risk score named ARUC score (Assess-
ment of Risk of multidrUg resistant pathogens in Community-onset pneumonia) was
MDR Pathogens in Pneumonia
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developed. The resulting score values were derived by rounding the beta coefficients (logarithm
of the odds-ratios).
We evaluated discrimination using receiver operating characteristic curves (ROC). We
compared ROC curves for the different scores; we adjust the probability using the Sidak meth-
od. The calibration of the model was evaluated by the goodness-of-fit Hosmer-Lemeshow
χ2 statistic.
We calculated sensitivity, specificity, negative and positive predictive values (with 95% con-
fidence intervals) for the cut-off point of the score in order to predict the MDR status. We also
calculated negative and positive likelihood ratios (with 95% confidence intervals). All tests
were two-tailed, and a P value< 0.05 was considered significant. All computations were carried
out with R version 3.0.2, SPSS 20.0 for Windows (SPSS Inc., Chicago, IL) and STATA v.12.
Results
During the study period a total of 1,365 patients were assessed for eligibility, and 900 were fi-
nally included in the study: 536 patients had CAP and 364 HCAP. A consort diagram describ-
ing the study flow is presented in Fig 1.
Overall, an etiologic diagnosis was obtained in 300 patients (33.3%). Pneumonia was caused
by a MDR pathogen (group MDR+) in 99 cases (11%), while the remaining patients had no
Fig 1. Study flow diagram. Legend. ED: emergency department; HAP: hospital-acquired pneumonia.
doi:10.1371/journal.pone.0119528.g001
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MDR pathogen isolation (group MDR-). Etiologic agents of pneumonia in our study popula-
tion are described in Table 1.
At least one microbiological test was performed in the 70% of patients enrolled. As de-
scribed in Fig 2, the majority of patients with MDR isolates belonged to the HCAP group
(68.7%) but a significant percentage (31.3%) was also encountered in the CAP group.
Comparison of demographics, clinical features and outcome of patients included in the
MDR+ and MDR-groups are summarized in Table 2.
The univariate analysis between patients with non-MDR etiology versus those without etio-
logic diagnosis is presented in S1 Table (see supplementary material). Compared to MDR-
group, almost all patients included in the MDR+ group belonged to the high severity classes
(IV or V) of PSI, received more frequently a previous antibiotic therapy with quinolones,
macrolides or 3rd generation cephalosporins, had higher median Charlson score, were more
likely to receive an inappropriate therapy, had higher mean duration of antibiotic therapy,
higher mean LOS, and a significantly higher mortality rate.
Most patients included in the MDR+ group had an Aliberti score3 (70.7% vs 42.2%,
p<0.001), a Shorr score1 (69.7% vs 37.8%, p<0.001), and a Shindo score2 (60.6% vs
37.3%, p<0.001). As shown in Table 3, the final logistic regression model identified four vari-
ables significantly associated with MDR etiology including 1) one risk factor for HCAP, 2) bi-
lateral pulmonary infiltration, 3) the presence of pleural effusion, and 4) the severity of
respiratory impairment calculated by use of PaO2/FiO2 ratio.
Table 4summarizes the risk score (ARUC score) for MDR pneumonia and the designation
of points. The total possible score ranged from 0 to 3.5.
The prevalence of MDR pathogens rose with increasing score after stratifying the scores
into Low (<0.5), and High (3) risk (see Fig 3).
When the score was<0.5 the prevalence of MDR pathogens was very low (3%), while the
prevalence climbed to 41% when the score was3.
As a screening test, a negative ARUC score (<0.5) had a good sensitivity (75%) and a strong
NPP (95%), while a positive score3 had a high specificity (92%) and a strong PPV (93%).
Fig 4compares sensitivity, specificity, PPV, and NPV of ARUC, Aliberti, Shorr, and
Shindo scores.
Table 1. Etiology of 300 isolations in the study population.
Isolation of MDR strain n = 99 patients Isolation of non-MDR strain n = 201 patients
MRSA 42 (42.4%) Streptococcus pneumoniae 69 (34.3%)
Pseudomonas aeruginosa 11 (11.1%) MSSA 31 (15.4%)
Klebsiella pneumonia 10 (10.1%) Mycoplasma pneumoniae 15 (7.5%)
Serratia marcescens 8 (8.1%) Pseudomonas aeruginosa 15 (7.5%)
Escherichia coli 7 (7.1%) Klebsiella pneumoniae 14 (7%)
MRSA + P. aeruginosa 6 (6.1%) Haemophilus influenzae 13 (6.6%)
Acinetobacter baumannii 6 (6.1%) Clamydia pneumoniae 10 (4.9%)
Enterobacter cloacae 4 (4%) Mycobacterium spp 10 (4.9%)
E. cloacae + S. maltophilia 2 (2%) Legionella pneumophila 10 (4.9%)
MRSA + A. baumannii 2 (2%) Enterobacter cloacae 8 (4%)
Stenotrophomonas maltophilia 1 (1%) Escherichia coli 6 (3%)
Legend. MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; MDR: multidrug-resistant.
doi:10.1371/journal.pone.0119528.t001
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The area under curve (AUC) of our model was higher (0.76, 95% Confidence Interval [CI]
0.71–0.82), than that of Aliberti (AUC = 0.65, 95%CI 0.59–0.71), Shorr (AUC = 0.65, 95%CI
0.60–0.70), and Shindo scores (AUC = 0.65, 95%CI 0.59–0.71). The goodness-of-fit Hosmer-
Lemeshow χ2 was 7.64 (p = 0.469) for ARUC score, 7.45 (p = 0.489) for Shorr score, 10.25
(p = 0.248) for Aliberti score, and 11.91 (p = 0.155) for Shindo score.
The performance of the score was evaluated on 929 patients with pneumonia with a median
age of 80 (IQR 70–87) years. Most of patients had multiple comorbidities and 35% were classi-
fied as having HCAP. An attempt to microbiological diagnosis was made in 857 patients with
an overall rate of etiological diagnosis of 23.2%. In 49 out of 199 patients (24.6%) with microbi-
ological diagnosis a MDR pathogen was isolated (5.2% of the overall cohort). Clinical and mi-
crobiological characteristics of the validation cohort are listed in S2 Table (see supplementary
material). The distribution of ARUC score’s variables in the validation cohort is detailed in S3
Table (see supplementary material). Overall, the 4% of population belonged to the low risk
class of ARUC score, while the 39% belonged to the high risk class. A positive ARUC score
(0.5) showed a sensitivity of 85% and a specificity of 50%, a PPV of 28% and a NPV of 94%
to predict isolation of MDR pathogen. As reported in Fig 5, the AUC of this model was 0.68
(95% CI 0.60–0.77).
Fig 2. Distribution of MDR pathogens in CAP and HCAP populations. Legend. MDR: multidrug-resistant; CAP: community-acquired pneumonia; HCAP:
health-care associated pneumonia.
doi:10.1371/journal.pone.0119528.g002
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Discussion
The relevant and novel findings of this study are that 1) in the context of patients with commu-
nity-onset pneumonia exists a proportion of patients who develop an infection due to MDR
pathogens, 2) MDR isolation is associated with inappropriate empirical antibiotic therapy and
accounts for an unacceptable related mortality, 3) HCAP definition alone is not sufficient to
Table 2. Univariate analysis of MDR-group compared to patients without MDR isolation.
Variables MDR+ MDR- OR 95% CI p
n = 99 patients n = 801 patients
Age (median) 78 82 1.02 1.00–1.03 0.029
Male sex 55 (61.2%) 490 (55.5%) 1.26 0.52–1.21 0.281
PSI IV-V class 98 (99%) 637 (69.7%) 2.71 1.78–4.15 <0.001
Adherence to guidelines 31 (26%) 421 (45.9%) 0.41 0.26–0.62 <0.001
 2 comorbidities 37 (37.4%) 161 (20.1%) 2.27 1.28–3.34 <0.001
Charlson Comorbidity Index (median) 4.7 3.2 3.12 2.22–5.34 <0.001
Aliberti score  3 70 (70.7%) 338 (42.2%) 3.72 2.1–5.7 <0.001
Shorr score  1 69 (69.7%) 303 (37.8%) 4.1 2.56–6.11 <0.001
Shindo score  2 60 (60.6%) 299 (37.3%) 2.86 1.87–4.48 <0.001
Heart failure 69 (69.7%) 217 (27.1%) 4.44 2.93–6.77 <0.001
Chronic hepatitis 16 (16.1%) 67 (8.3%) 1.78 1.09–2.76 0.016
Diabetes 19 (19.2%) 151 (18.8%) 1.28 0.78–2.14 0.893
Renal failure 43 (43.4%) 144 (17.9%) 2.56 1.49–4.51 <0.001
COPD 40 (40.4%) 255 (31.8%) 1.76 0.91–2.22 0.09
Dementia 21 (21.2%) 180 (22.4%) 1.08 0.59–1.45 0.898
HCAP 68 (68.7%) 296 (36.9%) 4.11 2.34–6.12 <0.001
Neoplasm 21 (21.2%) 170 (21.2%) 0.29 0.12–0.87 1.0
Pleural effusion 56 (56.5%) 329 (41.1%) 2.72 1.79–3.84 0.005
Malnutrition 48 (48.5%) 101 (12.6%) 4.85 3.02–7.22 <0.001
PPI/H2 blockers 54 (54.5%) 239 (29.8%) 2.82 1.89–4.71 <0.001
Previous surgery (30 days) 13 (13.1%) 19 (2.3%) 5.9 2.81–12.1 <0.001
Bilateral pulmonary infiltration 42 (42.4%) 182 (22.7%) 2.45 1.77–3.31 <0.001
Fever > 38°C 48 (48.5%) 437 (54.5%) 0.28 0.12–0.67 0.285
Increased ultrasensitive troponin 32 (32.3%) 215 (26.8%) 1.34 1.02–2.12 0.04
Multilobar pulmonary extension 24 (24.2%) 166 (20.7%) 1.54 1.11–2.18 0.04
PaO2/FiO2 < 300 71 (71.7%) 265 (33.1%) 3.79 2.42–4.91 <0.001
Inappropriate therapy 83 (83.8%) 19 (2.4%) 277 134.7–434.1 <0.001
Quinolones or macrolide or cephalosporins in the previous 30 days 71 (71.7%) 272 (33.9%) 5.14 3.34–8.81 <0.001
NIV 7 (7%) 20 (2.5%) 2.81 1.31–5.9 0.022
Platelets < 150.000 mm3 28 (28.3%) 130 (13.5%) 1.18 0.95–1.69 0.001
SOFA score 3.5 2.3 2.8 2.23–2.94 <0.001
Mean length of hospitalization (days) 18.9 16.7 2.95 1.82–2.67 0.005
Mean length of therapy (days) 19.2 14.2 1.62 1.43–1.99 0.006
ICU admission 12 (12.2%) 12 (1.5%) 1.89 1.54–3.22 0.002
Severe sepsis or septic shock 25 (25.2%) 74 (7.7%) 2.63 2.34–3.78 <0.001
30-day mortality 40 (40.4%) 89 (11.1%) 2.72 1.62–3.82 <0.001
In-hospital mortality 54 (54.5%) 102 (12.7%) 6.9 3.91–8.92 <0.001
Legend. MDR: multidrug-resistant; PSI: pneumonia severity index; COPD: chronic obstructive pulmonary disease; HCAP: healthcare-associated
pneumonia; PPI: proton pump inhibitors; NIV: non-invasive ventilation; SOFA: sequential organ failure assessment; ICU: intensive care unit.
doi:10.1371/journal.pone.0119528.t002
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discriminate patients at risk for MDR pathogens, and 4) the ARUC score, a new prediction
rule, appears as a useful tool to help physicians in an early recognition of patients living in the
community with pneumonia due to MDR pathogens.
The first key point of our study is that patients with community-onset pneumonia due to
MDR pathogens have a high 30-day mortality rate (40.4%) and a high likelihood to receive an
inappropriate initial antibiotic therapy (83.8%). Aliberti and coworkers, analyzing a population
of 935 patients, observed that patients with risk factors for MDR had higher mortality rate than
those who had not (22% vs 10%). Compared to abovementioned study, we found a higher pro-
portion of MDR isolates (11%) and also higher mortality rates. The high mortality observed in
our patients appears directly related to a high frequency of empirical inadequate antibiotic
therapy. Moreover, another factor which may also explain the high mortality rate is the fact
that most of our patients were old and critically ill and that we focused our analysis in patients
who were hospitalized in medical wards for at least 48 hours; thus patients with mild or moder-
ate pneumonia were excluded from the study.
Some reports describe the increasing prevalence of MDR organisms in subjects presenting
de novo to the hospital [1,4,6,9,10,19,20,21]. The concept of HCAP, which was proposed in
2005 [16], was meant to serve as a tool to help clinicians to stratify individuals with high likeli-
hood to have pneumonia due to a resistant pathogen, like MRSA, P. aeruginosa or other MDR
gram-negative bacilli. Many studies have documented that HCAP is associated with increased
mortality and higher risk of etiology due to MDR pathogens [1–4,6,8–10,19–22], and a pro-
spective interventional study on elderly patients with pneumonia showed clinical benefit of an
empirical broad-spectrum antibiotic therapy [23]. However, some authors have expressed con-
cern that antibiotic treatment decisions driven by the concept of HCAP might lead to excessive
prescription and abuse of broad-spectrum anti-infectives [5,7], leading to unnecessary costs
Table 3. Multivariate analysis of factors associated with MDR isolation.
Variables p OR 95% CI VIF
Bilateral Pulmonary Infiltration 0.018 1.75 1.09–
2.79
1.05
Pleural effusion <0.001 1.95 1.25–
3.07
1.02
At least one of HCAP criteria: Previous hospitalization (3 months),
dialysis, i.v. therapy previous 30 days, residence in nursing home or
long-term care facility
<0.001 2.52 1.57–
4.09
1.07
PaO2/FiO2 ratio < 300 <0.001 4.08 2.55–
6.67
1.03
Legend. MDR: multidrug-resistant; HCAP: health-care associated pneumonia.
doi:10.1371/journal.pone.0119528.t003
Table 4. ARUC score for early identification of patients with MDR-pneumonia.
HCAP criteria (at least one of the following): Previous hospitalization (3 months), dialysis,
i.v. therapy previous 30 days, residence in nursing home or long-term care facility
+ 1 pts
Bilateral Pulmonary Infiltration + 0.5 pts
Pleural effusion + 0.5 pts
PaO2/FiO2 < 300 + 1.5 pts
Legend. MDR: multidrug-resistant; HCAP: health-care associated pneumonia; COPD: chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0119528.t004
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and promote resistance. Our study confirms that HCAP per se has limited value in segregating
subjects with potentially resistant infections: as a matter of fact a significant percentage of cases
of pneumonia caused by MDR-bacteria (31.3%) were encountered in the CAP group [24, 25,
26].
Since HCAP definition alone is not sufficient to predict the risk for MDR pathogens, the de-
velopment of risk stratification scoring tools provide to physicians an easy-to-use mechanism
to determine which patients presenting with pneumonia may require broad-spectrum antibiot-
ic coverage. We evaluated the performance of 3 existing scores and developed a new risk score
(ARUC score) for the assessment of MDR pathogens in patients with community-onset pneu-
monia. Both C statistic of the model and goodness-of-fit Hosmer-Lemeshow χ2 statistic con-
firmed a good discriminatory power of ARUC score in the early identification of patients with
pneumonia due to MDR organisms. Of importance a score<0.5 had a good sensitivity and a
strong NPP, while a score3 had a high specificity and strong PPV. These results highlight
the role of ARUC score in selecting patients at lowest and highest risk for carrying MDR
pathogens.
The strength of ARUC score may be that it is derived from a population of severely ill elder-
ly patients, and in the majority of our patients were contemporary present at least two or more
recognized risk factors for MDR; thus we had the chance to explore additional factors possibly
Fig 3. Risk stratification of MDR isolation on the basis of ARUC score. Legend. MDR: multidrug-resistant.
doi:10.1371/journal.pone.0119528.g003
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related to an infection by a MDR strain. In addition ARUC score takes in account not only pre-
disposing host factors for MDR but also clinical-radiological parameters evaluating the severity
of illness, such as PaO2/FiO2 ratio, bilateral pulmonary infiltration and the presence of pleural
effusion. A moderately good performance of this bedside score was confirmed in a multicenter
Spanish population of elderly patients with pneumonia.
Another message of our article is that pneumonia due to MDR bacteria may be more severe
than other causes, and is more frequently associated with higher degree of respiratory im-
pairment expressed as PaO2/FiO2 ratio. This is not surprising since the involved species (S. au-
reus, P. aeuginosa and other MDR Enterobacteriaceae) are particularly virulent and frequently
cause bilateral pneumonia; moreover, initial outpatient antibiotics usually prescribed in pa-
tients with CAP (e.g. macrolides, cephalosporins, or fluoroquinolones) are ineffective in pa-
tients with MDR etiology and this may lead to a more complicated clinical course. As matter of
fact, Khawaja and coworkers found that the microbes causing severe CAP were different from
Fig 4. ROC curves of ARUC, Aliberti, Shorr and Shindo scores. Legend. PPV: positive predictive value; NPV: negative predictive value.
doi:10.1371/journal.pone.0119528.g004
MDR Pathogens in Pneumonia
PLOS ONE | DOI:10.1371/journal.pone.0119528 April 10, 2015 11 / 16
the usual spectrum: Staphylococcus aureus and Pseudomonas aeruginosa were the common
causative pathogens and were associated with high mortality [27].
Our study has important limitations: culture data were not always obtained in every case of
suspected pneumonia, which introduces a selection bias. Thus percentage of MDR bacteria
may be underestimated, and we cannot exclude that a proportion of patients who died without
definite diagnosis had a MDR etiology. Another limitation is that the ARUC score was derived
Fig 5. ROC curves of ARUC score on the Spanish population.
doi:10.1371/journal.pone.0119528.g005
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by comparing the MDR population to the composite group of patients without MDR etiology
or with unknown etiology; however, we did not find significant differences between these latter
groups in term of baseline characteristics and outcomes, and this finding reduces the potential
bias of this analysis. Finally, since ARUC score showed a good but not optimal discrimination
power (AUC 0.68 in the validation cohort) future large studies are needed to assess the better
scoring tool for the early identification of patients with pneumonia due to MDR pathogens.
In conclusion a rapid identification of patients with infection due to MDR pathogens seems
crucial to reduce mortality for community-onset pneumonia. Physicians working in ED should
adopt simple risk scores, like ARUC score, to select the most appropriate antibiotic regimens.
This individualized approach may help clinicians to identify those patients who need an empir-
ical broad-spectrum antibiotic therapy [28].
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